# California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations

> **NIH NIH U54** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $1,803,929

## Abstract

ABSTRACT OF THE OVERALL COMPONENT
Human papillomavirus (HPV)-associated cancers are major causes of morbidity and mortality in the Latin
American and Caribbean region. Beyond universal HPV vaccination programs, cost-effective strategies are
needed to enhance early detection and improve non-invasive management of precancerous lesions among
HIV-positive women and men. Little is known about the performance of newer screening technologies in HIV-
positive women in Latin America. The California-Mexico-Puerto Rico (CAMPO) Consortium will perform
three clinical research studies focused on the prevention of cervical cancer among HIV-positive women in
Mexico and Puerto Rico. Study 1 will examine new screening algorithms for cervical high-grade squamous
intraepithelial lesions (HSIL) in 4000 HIV-positive women in Mexico and Puerto Rico. This study will evaluate
triage strategies that include liquid-based cytology, point-of-care genotyping for high-risk HPV DNA, E6/7
oncoprotein expression, and viral and host methylation to detect cervical HSIL among HIV-positive women. We
hypothesize that a test with high sensitivity, followed by a test with high specificity, will provide for optimal
sensitivity, specificity and predictive value for cervical HSIL in this population. We will also screen 1000 HIV-
positive men who have sex with men (MSM) for anal HSIL to identify men with anal HSIL for our HSIL
treatment studies (Studies 2 and 3) and evaluate anal HSIL screening algorithms using the same tests as
those being done in the cervix. Through the cases of cervical and anal HSIL identified in these screening
studies, the CAMPO Consortium will also develop and implement two randomized placebo-controlled
treatment studies for HSIL. Study 2 will evaluate the impact of anogenital probiotic use on anal and cervical
microbiota profiles and the relationship to anal and cervical HSIL regression in 600 HIV-positive women and
men as well as reduction of high-risk HPV DNA persistence among those with no lesions. Study 3 will evaluate
the safety and efficacy of a multivalent replication-defective adenovirus-based therapeutic HPV vaccine to treat
cervical and anal HSIL in 300 HIV-positive women and men and identify immune response correlates of HSIL
regression. Together, the proposed studies aim to develop novel strategies for cervical and anal cancer
prevention for HIV-positive adults. The CAMPO Consortium will include three Cores to support the
implementation of the Clinical Trials Program: (1) a Central Laboratory Core; (2) a Data Management and
Statistical Core; and (3) an Administrative and Coordinating Core. Furthermore, investigators within the
CAMPO Consortium will provide mentorship to support early career investigators from Mexico and Puerto
Rico, fostering the next generation of cancer researchers focused on HPV-related cancers and HIV with the
region. Through its unique combination of innovative science with research capacity-building and mentorship,
we expect the CA...

## Key facts

- **NIH application ID:** 10690029
- **Project number:** 5U54CA242646-05
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** ANA Patricia ORTIZ
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,803,929
- **Award type:** 5
- **Project period:** 2019-09-12 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10690029

## Citation

> US National Institutes of Health, RePORTER application 10690029, California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations (5U54CA242646-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10690029. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*